Oligon is a pre-clinical stage company advancing its SeekR™ platform, which enables self-delivery of siRNA to multiple cell types beyond the liver. The lead asset is a T-cell targeting siRNA therapy for treating multiple oncology and immunology indications
Oncology & Immunology
CTI LSF III
Lead
Director & Observer
September 3, 2026
Active
Seed
Oligon has a unique and differentiated siRNA delivery platform for the treatment of extrahepatic diseases. The modality is purely synthetic combining dual targeting RNA aptamers flanking two siRNAs enhancing the specificity and potency.
